Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.

History

The company was founded in 1988 as Lidak Pharmaceuticals, Inc. with a focus on research based human therapeutics. In the mid-1990s the name changed to Avanir Pharmaceuticals, Inc. and the mission was re-focused to the areas of cardiovascular, autoimmune and infectious diseases. In 1999, the company in-licensed NUEDEXTA® and began clinical development.

NUEDEXTA – A Story of Perseverance and Serendipity

In late 2006, the company received an approvable letter from the FDA for NUEDEXTA. The company quickly moved in a different direction and strategized for the future. In early 2007, the company met with the FDA to establish the path for future FDA approval of NUEDEXTA, which included a drug reformulation and several more years of clinical trials.

Following the approvable letter, Avanir went from a company with a market capitalization of $600 million and 200 employees to an organization with a sub $100 million market capitalization and less than 30 employees. By redirecting its efforts to develop and commercialize central nervous system therapies for conditions of high unmet medical need, Avanir has now transformed itself into a commercial stage biopharmaceutical company with about 300 employees, a revitalized shareholder base and a path forward for success.